@article{oai:kanazawa-u.repo.nii.ac.jp:00014831,
 author = {Ono, Shunsuke and Kurotani, Takako and Nakasone, Tadashi and Honda, Mitsuo and Boon-Long, Jotika and Sawanpanyalert, Pathom and 木村, 和子},
 issue = {3},
 journal = {Japanese Journal of Infectious Diseases},
 month = {Jan},
 note = {The prevalence of adult HIV/AIDS in Thailand is declining due to intense prevention strategies, but it still continues to be a critical health problem with a prevalence of 1.5%. Several HIV vaccine candidates for the prevention of HIV infection or progress to AIDS were examined in clinical trials. We evaluated the cost-effectiveness of a vaccination regimen (rBCG prime-rDIs boost) currently in its pre-clinical phase. The cost-effectiveness of three interventions (vaccination, highly active antiretroviral treatment [HAART], and the combination of the two) through an existing vaccination program was assessed in a Markov model. The disability-adjusted life year (DALY) was the main effectiveness measure. In the base case the efficacy of the vaccine for preventing HIV infection was assumed to be 30%. The cost of the vaccine was estimated on the basis of its predicted production capacities in Thailand. The incremental cost-effectiveness ratios of vaccination, HAART, and the combination were about $US 75, $US 610, and $US 267 per DALY averted compared with the do-nothing strategy in the base case. The HAART-only strategy seemed to be less cost-effective than the other options under the current assumptions. Sensitivity analyses indicated that the new HIV infection rate and the vaccine efficacy could affect the results., 東京大学大学院薬学系研究科 医薬品評価科学講座, 元・金沢大学大学院自然科学研究科},
 pages = {168--173},
 title = {Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand},
 volume = {59},
 year = {2006}
}